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70% (CI57–83) at two, three, and six months, respectively.Effects of dual blockade of the renin-angiotensin system in pri-
All comparisons with baseline achieved statistical significancemary proteinuric nephropathies.
and treatment with combination therapy was statistically moreBackground. Blockade of the renin-angiotensin system (RAS)
with angiotensin converting enzyme (ACE) inhibitors or with effective in proteinuria reduction than treatment with cande-
angiotensin II type 1 (AT1) receptor blockers has been shown sartan alone at two and six months (P  0.004 and P  0.023,
to reduce proteinuria and to slow down the progression of respectively) and than treatment with lisinopril only at two
renal disease in diabetic and non-diabetic primary proteinuric months (P  0.03).
nephropathies. Additionally, this beneficial effect is not depen- Conclusion. Dual blockade of the renin-angiotensin system
dent on blood pressure control. with ACE inhibitors and AT1 receptor blockers produces a
Methods. To assess and compare the effects of lisinopril (up beneficial antiproteinuric effect that could not be explained
to 40 mg/day), candesartan (up to 32 mg/day) and combination only by the systemic blood pressure reduction. All treatments
therapy (lisinopril up to 20 mg/day plus candesartan up to 16 were well tolerated.
mg/day) on urinary protein excretion, 45 patients with primary
proteinuric nephropathies (urinary protein/creatinine ratio 3.8
2.4 g/g) and normal or slightly reduced renal function (CCr
95  33 mL/min) were enrolled in a six month multicenter, There is clear evidence that pharmacological blockade
prospective, open, randomized, active-controlled and parallel- of the renin-angiotensin system (RAS) with angiotensingroup trial with 1:1:1 allocation. Blood pressure goal was set
converting enzyme (ACE) inhibitors slows the progres-at or below 125/75 mm Hg for all patients, with additional
antihypertensive medication prescribed if required. sion of renal disease in diabetic [1–4] and non-diabetic
Results. Renal function, estimated by creatinine clearance, nephropathies [5, 6], a beneficial effect not only related
remained stable throughout the study. Hyperkalemia (K 5.5 to blood pressure control [7]. More recently, three studiesmmol/L) was detected in 3.1% of all measurements in follow-
have shown the nephroprotective properties of angioten-up, and was more frequent in patients treated with lisinopril
sin II type 1 (AT1) receptor blockers (ARB) in patientsalone or lisinopril plus candesartan (P  0.001) than in those
on candesartan alone. No other relevant adverse event was with type 2 diabetic nephropathies [8–10]. Both classes
recorded. The blood pressure goal (125/75 mm Hg) was of drugs have demonstrated a relevant antiproteinuric
achieved by week 4 in all treatment groups (P  0.005 when
effect and the reduction of proteinuria appears to be acompared to baseline), and afterwards the mean systolic and
surrogate marker of the nephroprotective effect obtaineddiastolic blood pressure remained below these values until
the end of the trial with no statistically significant differences with RAS inhibition [11, 12].
between groups. Urinary protein/creatinine ratio (percentage However, not all patients respond similarly to these
reduction 95% confidence intervals CI) decreased in patients
treatments. Some patients exhibit a significant beneficialtreated with lisinopril alone to 33% (CI 12–56) to 31%
response with reduction of proteinuria and preservation(CI 0–68) and to 50% (CI 9–90), in patients treated with
candesartan to28% (CI12–45), to41% (CI30–52) and of renal function while others do not. An insufficient
to48% (CI32–63), in patients treated with the combination response to ACE inhibition might be explained by the
of both to 60% (CI 44–77) to 54% (CI 38–69) and to
incomplete blockade of the RAS obtained with ACE
inhibitors, which are unable to block completely the for-
mation of angiotensin II (Ang II), because some genera-Key words: ACE inhibitors, angiotensin receptor blockers, proteinuria,
non-diabetic nephropathies, progressive renal disease. tion of Ang II is produced via other non-ACE pathways
[13]. Furthermore, Ang II levels return to normal values 2002 by the International Society of Nephrology
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after chronic therapy with ACE inhibition, the so-called Study design
“ACE escape phenomenon” [14]. This multicenter, prospective, open, randomized, ac-
In the search of new alternatives that could improve tive controlled and parallel group trial was conducted in
the antiproteinuric and nephroprotective effects of RAS seven centers in Spain. The study was approved by the
blockers, we believe that the association of ACE inhibi- appropriate institutional review boards and was conducted
tors and ARB might prove useful. ARB produces a com- according to good clinical practice. All patients provided
plete blockade of the RAS and stimulates the vasodilat- informed written consent before entry into the study.
ing and non-proliferative actions of Ang II via the AT2 After a 14-day washout period with metoprolol up to
receptor [15]. Furthermore, ACE inhibitors, but not 200 mg/day and/or hydrochlorothiazide up to 50 mg/day
ARB, inhibit the metabolism of kinins, which increases as antihypertensive drugs if needed for patients receiving
the levels of bradykinin, also a potent vasodilator [16]. ACE inhibitors or AT1 antagonists prior to inclusion,
Recently, some authors have reported a superior effect patients were randomly allocated to one of the three treat-
of the combination of ACE inhibition and ARB on micro- ment groups in a 1:1:1 ratio. Treatment lasted 24 weeks
albuminuria and on clinical proteinuria in patients with for all groups. Randomization was centralized with blocks
primary nephropathies [17–19], and in type 1 and type 2 of six and codes were kept in sealed envelopes in each
center.diabetic patients [20, 21].
In order to evaluate the effects of dual blockade of
Primary objectivethe RAS system in primary proteinuric nephropathies,
The primary objective was a reduction in proteinuriawe designed a multicenter, prospective, open, random-
excretion with lisinopril, candesartan or a combinationized, active controlled and parallel group trial to compare
of both therapies in primary proteinuric nephropathies.the effects of three different drug regimens—with the
ACE inhibitor lisinopril, combined with an ARB, cande-
Interventionssartan, versus lisinopril or candesartan alone at equiva-
After a two-week wash-out period, patients were ran-lent doses—in a setting of strict blood pressure control.
domized to three treatment groups and received once
daily either lisinopril 10 mg, candesartan 8 mg, or lisino-
METHODS pril 5 mg plus candesartan 4 mg for two weeks. Dosage
of medication was doubled every two weeks up to lisino-Eligibility criteria
pril 40 mg, candesartan 32 mg, or lisinopril 20 mg plusMale and female outpatients between 18 and 80 years
candesartan 16 mg once daily, if either systolic bloodold with primary proteinuric nephropathies for more
pressure was higher than 125 mm Hg or diastolic greaterthan six months (renal biopsy was recommended al-
than 75 mm Hg. Additional antihypertensive medication,though not required) were eligible for inclusion into the
such as beta-blockers, calcium channel blockers and/ortrial. Patients were included irrespective of their blood
thiazide diuretics alone or in combination were subse-pressure if proteinuria measured by the sulfosalicylic
quently introduced from weeks 6 to 12 in order to achieveacid method was greater than 2 g in a least two 24-
blood pressure goal, that is, BP 125/75 mm Hg in allhour urine collections, and the glomerular filtration rate
groups. All concomitant therapy was recorded, specially
(GFR), estimated by creatinine clearance was greater those drugs known to influence glomerular filtration
than 50 mL/min/1.73 m2. rate (GFR) and proteinuria such as non-steroidal anti-
inflammatory drugs (NSAIDs). Adverse events were re-Exclusion criteria
corded at each visit in response to open questions or as
Nephrotic patients with serum albumin 3.0 g/dL as observed by investigators.
well as those with hypertension stage 3 (SBP180 mm Hg
and/or DBP110 mm Hg), hyperkalemia (5.0 mmol/L), Drop-outs
secondary glomerular diseases, systemic diseases [diabe- Patients discontinued the trial in case of withdrawal of
tes mellitus, amyloidosis, systemic lupus erythematosus consent, hyperkalemia (6.5 mmol/L) despite treatment
(SLE)], or those with any severe cardiovascular event with cation exchange resins, worsening of renal function
in the last three months before randomization were ex- defined by an increase from baseline serum creatinine
cluded from the study. Patients with severe cardiac, pul- greater than 50% and confirmed in two occasions ten
monary or hepatic disease, HIV infection, and neoplasia days apart, any severe adverse event or intercurrent med-
also were excluded from the trial, as were those who ical problem requiring hospitalization, and cough in pa-
received corticosteroids and/or immunosuppressive ther- tients on ACE inhibitor therapy.
apy in the last six months before entry into the study.
OutcomesWomen of childbearing age were included only after a
negative gestation test and if they were using an effective Follow-up was performed at the out-patient clinic for
a total of eight study visits, two weeks before randomiza-method of birth control.
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Table 1. Summary of baseline characteristics of patients with
proteinuric nephropathies
Candesartan 
Candesartan Lisinopril lisinopril
(N  15) (N  14) (N  16)
Men/women N 10/5 12/2 9/7
Age years 4518 5016 4213
BMI kg/m2 26.72.6 26.43.9 27.15.6
Blood pressure mm Hg
Systolic 13314 13520 13520
Diastolic 8011 8014 8410
Serum/plasma
SCr mg/dL 1.080.5 1.260.5 1.150.3
K mmol/L 4.30.3 4.30.3 4.50.3
Fig. 1. Percentage of patients who achieved the maximum, mediumAlbumin g/dL 3.60.4 3.60.5 3.50.5
and minimum dose of medication in each study group. Symbols are:Urine
() maximum; ( ) medium; () minimum.CCr mL/min 10436 8426 9634
Protein/creatinine 4.02.5 3.62.9 3.82.1
Data are meansSD. P  0.05 for all comparisons by chi-square, ANOVA
or Kruskal-Wallis tests, as appropriate.
RESULTS
Between October 2000 and June 2001, 46 patients with
primary proteinuric nephropathies were included intotion (visit 2), at inclusion and beginning of treatment
the trial, although one patient never took the study medi-(visit 0), and at 2, 4, 6, 8, 12 and 24 weeks after randomiza-
cation and was excluded from the study. There were 14tion for blood pressure measurements and titration of
women and 31 men evenly distributed among groupsmedication if needed, as stated above. At each visit, the
with a mean age of 45  16 years, a mean systolic bloodsitting blood pressure was measured thrice in the morning
pressure of 134  18 mm Hg, diastolic blood pressure ofafter five minutes of rest, with an interval of two minutes,
81 12 mm Hg, normal or slightly reduced renal functionabout 24 hours after the previous drug administration
(CCr 95  33 mL/min) and urinary protein/creatininewith an automatic device (Omron-705, CP), and the
ratio of 3.8 2.4 g/g of creatininte. There were no statisti-mean of the last two measurements was recorded. Com-
cally significant differences in the baseline characteristicsplete blood cell count, blood biochemistry (Na, K, Cl,
of patients by treatment group (Table 1). The maximum
HCO3, glucose, urea, creatinine, uric acid, Ca, P, albu- dose of candesartan (that is, 32 mg/day) was tolerated
min, protein, ASAT, ALAT, alkaline phosphatase, lipid by 56% of patients, whereas only 31% of patients
profile) and 24-hour urine collection (for protein, creati- achieved the maximum dose for lisinopril (40 mg/day),
nine, Na and K excretion) were performed at baseline and 35% of patients achieved maximum dose in the
and at weeks 6, 12 and 24 by standard methods. combination therapy group (lisinopril 20 mg/day plus
candesartan 16 mg/day). Medium doses (that is, lisinopril
Statistical methods 20 mg/day, candesartan 16 mg/day, and lisinopril 10 mg/
day plus candesartan 8 mg/day) were achieved in 35%,Values are expressed as mean  SD unless stated
23% and 39%, respectively (Fig. 1). Renal function, esti-otherwise. The values of urinary protein/creatinine are
mated by creatinine clearance, remained stable through-expressed as mean  SE with 95% confidence intervals.
out the study period, (Fig. 2) and there were no otherDifferences between means were assessed by repeated
changes in blood chemistries from baseline and betweenmeasures analysis of variance (ANOVA) for continuous
treatment groups at any point in the study (data notvariables if appropriate or by non-parametric analysis
shown except for potassium). No patient discontinuedfor variables that did not adjust to normal distribution.
the study because of hyperkalemia, however, serum po-Comparison of changes in proteinuria corrected by uri-
tassium was greater than 5.5 mmol/L in eight instancesnary creatinine excretion from baseline over time was per-
(3.1% of all measurements) during the study period,
formed with non-parametric analysis (Wilcoxon, Kruskal- but greater than 6.0 mmol/L in only two cases (Fig. 3).
Wallis and Mann-Whitney) since the variable did not Patients treated with lisinopril alone or lisinopril plus
follow a normal distribution even after logarithmic trans- candesartan had hyperkalemia greater than 5.5 mmol/L
formation. All analyses were based on intention to treat, (P  0.001) more frequently than those on candesartan
defined by inclusion into the trial and least one efficacy alone and mean potassium levels were also significantly
data available after randomization, with the last value higher at three months in comparison with baseline in
carried forward for missing values. All statistical analyses those patients treated with lisinopril or lisinopril plus
were performed with the SPSS 9.0 (SPSS Inc., Chicago, candesartan (Fig. 3). No other relevant adverse event
was observed.IL, USA) statistical software package.
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Fig. 2. Changes in creatinine clearance (CCr) by treatment groups through-
out the study period. Symbols are: (solid line) candesartan; (dashed Fig. 4. Blood pressure changes (mm Hg) by treatment groups through-
line) lisinopril; (dotted line) combination of candesartan and lisinopril out the study period. P 0.005 from first month until end of follow-up for
therapy. There were not significant changes between groups at any time. both systolic and diastolic compared to baseline, P was non-significant
between groups at any time point. Symbols are: (solid line) candesartan;
(dashed line) lisinopril; (dotted line) combination of candesartan and
lisinopril therapy.
Fig. 3. Mean  SD serum potassium (mmol/L) by treatment groups
during the study period. *P  0.036 comparing mean serum potassium
in the lisinopril group at 3 months with baseline data. **P  0.042
comparing mean serum potassium in the combination therapy group
at 3 months with baseline data. Symbols are: () baseline data; ( )
two months; ( ) 3 months; () 6 months. Fig. 5. Mean SE of urinary protein/creatinine ratio (g/g) by treament
groups during study period two, three and six months comparing with
baseline. Symbols are: () baseline data; ( ) two months; ( ) three
months; () six months.Although baseline systolic blood pressure was higher
in the groups of patients on ACE inhibitors and combina-
tion therapy, and diastolic blood pressure in the group on CI 32–63, P  0.001), and in patients treated with
combined therapy (Table 1), the differences did not reach combination therapy (that is, lisinopril plus candesartan)
statistical significance. The blood pressure goal, that is, from 3.8  0.53 at baseline to 1.55  0.41 at two months
125/75 mm Hg, was achieved by week 4 in all treatment (60%, CI 44–77, P  0.004) to 1.89  0.51 (54%,
groups (P 0.005 when compared to baseline), and after- CI 38–69, P  0.001) at three months and to 1.00 
wards the mean systolic and diastolic blood pressure re- 0.25 at six months (70%, CI57–83, P 0.001). Treat-
mained below that value until the end of the trial, with no ment with combination therapy was statistically more
statistical significant differences between groups (Fig. 4). effective in proteinuria reduction than candesartan alone
The urinary protein/creatinine ratio (mean  SE) at two and six months (P  0.004 and P  0.023, respec-
(percentage reduction 95% confidence intervals CI) de- tively) and than lisinopril alone only at two months (P
creased in patients treated with lisinopril alone from 3.6 0.03). The reduction in proteinuria was not significantly
0.77 at baseline to 2.44  0.97 at two months (33%, different between groups at three months (Fig. 5).
CI 12–56, P  0.008) to 2.54  0.70 at three months
(31%, CI 0–68, P  0.019) and to 1.83  0.68 at six
DISCUSSIONmonths (50%, CI9–90, P 0.013), in patients treated
with candesartan alone from 3.99  0.63 at baseline to The results of this clinical trial show a clear tendency
toward a more marked antiproteineuric effect of the com-3.14  0.67 at two months (28%, CI 12–45, P 
0.019) to 2.34  0.42 (41%, CI 30–52, P  0.001) at bination of ACE inhibitors and ARB than either drug
alone in non-diabetic renal patients with proteinuria.three months and to 2.18  0.49 at six months (48%,
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Treatment with combined therapy reduces proteinuria crease in blood pressure [20, 21]. Our data clearly show
that this reduction in proteinuria induced by the com-by 70% at 6 months, which is 30% superior to proteinuria
reduction obtained with either candesartan or lisinopril bined therapy is not only related to BP changes.
No change was observed in the creatinine clearancealone. Although this reduction was not significantly differ-
ent comparing lisinopril with the combination at the end in any of the three groups during the entire study period,
indicating that this more marked antiproteinuric effectof the study. It is important to note that this antiproteinuric
effect is obtained in situation of strict blood pressure con- during the combined therapy also was not related to
changes in renal function.trol (BP 125/75 mm of Hg) in all groups, which is the
target BP goal recommended by the Modification of Diet The reduction on proteinuria achieved by pharmaco-
logical blockade of the RAS with either ACE inhibitionin Renal Disease (MDRD) Study [22–24] in renal patients
with proteinuria greater than 1 g/day to slow the progres- [1, 7, 11] or ARB [8–10] did not parallel the blood pres-
sure response. Some authors have found an additionalsive decline in glomerular filtration rate observed in these
patients. This BP goal was achieved by week 4 in all antiproteinuric effect when patients were given greater
doses of ACE inhibitors or ARB [29, 30] and becausetreatment groups, and then remained controlled until the
end of the trial with no statistically significant differences urinary protein excretion provides a very strong clue in
relation to renal disease progression [12], it has beenbetween groups. This finding discounts that the differences
observed upon the reduction in proteinuria were ex- suggested that the dosage of ACE inhibition or ARB
selected for treatment in those patients with severe pro-plained only by the systemic BP effect.
The antiproteinuric effect achieved in this study was teinuria should be titrated up to the higher tolerated
dose to obtain a maximal antiproteinuric effect [31]. Theevident with all three therapeutic regimens, but it ap-
pears to be more pronounced with the combination of key question is whether the observed additive beneficial
effect of combined therapy could be achieved with aboth drugs despite that the maximal dose assigned in
each group was equivalent, and it was in the combined further increase in ACE inhibition or ARB dosage.
Trying to obviate this question, in our study the dos-therapy for each drug, half of the maximal dose achieved
with either drug alone. These data indicate that blocking ages of lisinopril and candesartan that were given to our
patients, most of whom were normotensive, were in thethe RAS with either ACE inhibitors or ARB produces a
significant antiproteinuric effect; however, the combined high range and double of the dosage recommended in
studies that achieved clear antiproteinuric and nephro-therapy of both offers an additional renal protection.
The rationale for combined therapy with ACE inhibi- protective effects with both drugs. The dosage of medica-
tion was doubled every two weeks up to lisinopril 40 mg,tors and ARB is based on the different mechanism of
these two drugs in the RAS blockade. Both drugs inhibit candesartan 32 mg or lisinopril 20 mg plus candesartan 16
mg once daily. The dose of each drug was unchanged,the action of Ang II. It is known that Ang II plays a
pivotal role in the pathophysiological course of renal unless intolerance appeared. To maintain the equiva-
lence, the dosage used in patients on the combined ther-disease progression. Ang II has a direct effect on vascular
tone and increases blood pressure, which plays a major apy was half of the dose received by patients on each
drug alone. The percentage of patients who reached therole in sustaining renal disease progression [25], but also
has a significant effect on intrarenal hemodynamics [26] maximal indicated dose was not different in patients
treated with combination therapy, 35% compared tosince it increases the filtration of protein across the glo-
merular capillary bed [27] and stimulates cell growth those on lisinopril, since 31% of them tolerated the maxi-
mal dose. Nonetheless, ARB candesartan was better tol-[28]. Ang II increases proteinuria throughout all these
mechanisms. However, ACE inhibition could not com- erated because 56% of the patients tolerated the maxi-
mal dose.pletely inhibit the generation of Ang II, which may be
produced via other non-ACE pathways [13]. In contrast, Both drugs alone and in combination were well toler-
ated. Not one patient discontinued the study because ofARB completely abolishes the action of Ang II through
blockading the AT1 receptor, producing an accumulation adverse effects. Although in most other studies compar-
ing ACE inhibitor and ARB no differences were foundof Ang II that stimulates the vasodilatory and antiprolif-
erative actions of Ang II mediated through the AT2 re- with regard to serum potassium [17–21], in our current
study, patients treated with lisinopril alone or lisinoprilceptor [15]. On the other hand, ACE inhibitors but not
ARB, decreases degradation of bradykinin, which is a plus candesartan more frequently had hyperkalemia than
those on candesartan alone. These results agree with thepotent vasodilator [16].
The additive antiproteinuric effects of the combina- data shown in other previous reports using valsartan
versus lisinopril in which valsartan induces less fre-tion of ACE inhibitors and ARB have been previously
observed in diabetic and non-diabetic kidney diseases, quently hyperkalemia than lisinopril in patients with re-
duced renal function [32]. Hyperkalemia, that is, serumalthough in some of these observations the more marked
antiproteinuric effect was associated with a greater de- potassium greater than 5.5 mmol/L, was detected on
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with nephropathy due to type 2 diabetes. N Engl J Med 345:851–eight instances throughout the study period and was
860, 2001
greater than 6.0 mmol/L in only two cases. All of these 11. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN):
Randomized placebo-controlled trial of effect of ramipril on de-eight cases had impaired renal function. Because of clini-
cline in glomerular filtration rate and risk to terminal renal failurecal relevance of high serum potassium levels, our data
in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863,
confirm that close monitoring of serum potassium is man- 1997
12. Remuzzi A, Bertani T: Pathophysiology of progressive nephropa-datory in patients with an impaired renal function treated
thies. N Engl J Med 339:1448–1456, 1998with RAS blockade, with a high dose of ACE inhibitor
13. Hollenberg NK, Fisher NDL, Price DA: Pathways for angioten-
either combined or not with ARB. No other relevant sin II generation in intact human tissue-evidence from comparative
pharmacological interruption of the renin system. Hypertensionadverse event was recorded.
32:387–392, 1998In conclusion, the present data show that combined
14. Nussberger J, Brunner DB, Waeber B, Brunner HR: Plasma
therapy with an ACE inhibitor and ARB produces a angiotensins under sustained converting enzyme inhibition with
enalapril in normal humans. J Hypertens 3(Suppl 3):S269–S270,beneficial antiproteinuric effect in patients with primary
1985proteinuric nephropathies. This antiproteinuric effect of
15. Siragy HM: The role of the AT2 receptor in hypertension. Am J
the dual blockade is not only dependent on blood pres- Hypertens 3 Suppl(5 Pt 2):62S–67S, 2000
16. Allen TJ, Cao Z, Youssef S, et al: The role of angiotensin II andsure reduction or changes in renal function. Whether
bradykinin in experimental diabetic nephropathy: Functional andthis antiproteinuric effect represents a surrogate marker
structural studies. Diabetes 46:1612–1618, 1997
of long-term preservation of renal function needs to be 17. Russo D, Pisano A, Balletta MM, et al: Additive antiproteinuric
effects of converting enzyme inhibitor and losartan in normoten-demonstrated and further prospective, long-term con-
sive patients with IgA nephropathy. Am J Kidney Dis 33:851–856,trolled trials are required in order to address this question.
1999
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